Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript - Thomson StreetEvents

Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript

Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript - Thomson StreetEvents
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript
Published Aug 10, 2020
14 pages (10391 words) — Published Aug 10, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALNY.OQ conference call or presentation 10-Aug-20 6:00pm GMT

  
Brief Excerpt:

... Medical School;Associate Chief of the Division of Nephrology...

  
Report Type:

Transcript

Source:
Company:
Alnylam Pharmaceuticals Inc
Ticker
ALNY.OQ
Time
6:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript – 2020-09-17 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 17-Sep-20 1:10pm GMT

Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript – 2020-09-16 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 16-Sep-20 7:20pm GMT

Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2020-09-15 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 15-Sep-20 1:30pm GMT

Alnylam Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript – 2020-09-10 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 10-Sep-20 2:45pm GMT

Alnylam Pharmaceuticals Inc Q2 2020 Earnings Call Summary – 2020-08-06 – US$ 54.00 – Edited Brief of ALNY.OQ earnings conference call or presentation 6-Aug-20 12:30pm GMT

Alnylam Pharmaceuticals Inc Q2 2020 Earnings Call Transcript – 2020-08-06 – US$ 54.00 – Edited Transcript of ALNY.OQ earnings conference call or presentation 6-Aug-20 12:30pm GMT

Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript – 2020-06-24 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 24-Jun-20 5:30pm GMT

Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Summary – 2020-06-07 – US$ 54.00 – Edited Brief of ALNY.OQ conference call or presentation 7-Jun-20 12:30pm GMT

Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Transcript – 2020-06-07 – US$ 54.00 – Edited Transcript of ALNY.OQ conference call or presentation 7-Jun-20 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript" Aug 10, 2020. Alacra Store. May 01, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-RNAi-Roundtable-Webcast-Series-Lumasiran-in-Development-for-the-Treatment-of-Primary-Hyperoxaluria-Type-I-T13304473>
  
APA:
Thomson StreetEvents. (2020). Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript Aug 10, 2020. New York, NY: Alacra Store. Retrieved May 01, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-RNAi-Roundtable-Webcast-Series-Lumasiran-in-Development-for-the-Treatment-of-Primary-Hyperoxaluria-Type-I-T13304473>
  
US$ 54.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.